A phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBVCLS-628 in adult patients with autosomal dominant polycystic kidney disease (ADPKD).
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: ABBVIE DEUTSCHLAND GMBH & CON K.G
- Phase: II
- Execution start: 31/03/2025
- End of execution: 30/06/2028
- IP: RAFAEL JOSE ESTEBAN DE LA ROSA